AI Article Synopsis
- HER2 upregulation is linked to worse outcomes in various cancers, highlighting a need for alternative treatments since current anti-HER2 therapies often result in relapses.
- The study used next-generation sequencing to analyze miRNAs and circRNAs in two breast cancer cell lines, finding 16 miRNAs influenced by HER2 expression, while circRNA levels remained stable.
- Among these, miR-223-3p, miR-421, and miR-21-5p were validated in a large patient cohort, suggesting they could be new targets to combat HER2 activation.
Article Abstract
HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and circRNAs in the cell-lines HB4a and C5.2, where the latter is a HER2-overexpressing clone of the former, and also from two different populations of their secreted extracellular vesicles. Whereas circRNA-levels were stable, we found at least 16 miRNAs apparently modulated by HER2-expression. The miR223-3p, miR-421 and miR-21-5p were validated in an independent cohort of 431 breast cancer patients from The Cancer Genome Atlas (TCGA). The consistent modulation of these molecules and their possible involvement in the HER2-axis makes them promising new targets to overcome HER2-activation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs-2018-0182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!